metformin has been researched along with Neuroendocrine Tumors in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barazeghi, E | 1 |
| Hellman, P | 1 |
| Norlén, O | 1 |
| Westin, G | 1 |
| Stålberg, P | 1 |
| Kurita, Y | 1 |
| Kobayashi, N | 1 |
| Hara, K | 1 |
| Mizuno, N | 1 |
| Kuwahara, T | 1 |
| Okuno, N | 1 |
| Haba, S | 1 |
| Tokuhisa, M | 1 |
| Hasegawa, S | 1 |
| Sato, T | 1 |
| Hosono, K | 1 |
| Kato, S | 1 |
| Kessoku, T | 1 |
| Endo, I | 1 |
| Shimizu, Y | 1 |
| Kubota, K | 1 |
| Nakajima, A | 1 |
| Ichikawa, Y | 1 |
| Niwa, Y | 1 |
| de Mestier, L | 1 |
| Védie, AL | 1 |
| Faron, M | 1 |
| Cros, J | 1 |
| Rebours, V | 1 |
| Hentic, O | 1 |
| Do Cao, C | 1 |
| Bardet, P | 1 |
| Lévy, P | 1 |
| Sauvanet, A | 1 |
| Ruszniewski, P | 1 |
| Hammel, P | 1 |
| Vázquez-Borrego, MC | 1 |
| Fuentes-Fayos, AC | 1 |
| Herrera-Martínez, AD | 1 |
| Venegas-Moreno, E | 1 |
| L-López, F | 1 |
| Fanciulli, A | 1 |
| Moreno-Moreno, P | 1 |
| Alhambra-Expósito, MR | 1 |
| Barrera-Martín, A | 1 |
| Dios, E | 1 |
| Blanco-Acevedo, C | 1 |
| Solivera, J | 1 |
| Granata, R | 1 |
| Kineman, RD | 1 |
| Gahete, MD | 1 |
| Soto-Moreno, A | 1 |
| Gálvez-Moreno, MA | 1 |
| Castaño, JP | 1 |
| Luque, RM | 1 |
| Hue-Fontaine, L | 1 |
| Lemelin, A | 1 |
| Forestier, J | 1 |
| Raverot, G | 1 |
| Milot, L | 1 |
| Robinson, P | 1 |
| Borson-Chazot, F | 1 |
| Lombard-Bohas, C | 1 |
| Walter, T | 1 |
| Vitali, E | 1 |
| Boemi, I | 1 |
| Piccini, S | 1 |
| Tarantola, G | 1 |
| Smiroldo, V | 1 |
| Lavezzi, E | 1 |
| Brambilla, T | 1 |
| Zerbi, A | 1 |
| Carnaghi, C | 2 |
| Mantovani, G | 1 |
| Spada, A | 1 |
| Lania, AG | 1 |
| Fan, Z | 1 |
| Gong, Y | 1 |
| Huang, Q | 1 |
| Yang, C | 1 |
| Cheng, H | 1 |
| Jin, K | 1 |
| Fan, K | 1 |
| Ni, Q | 1 |
| Yu, X | 1 |
| Luo, G | 1 |
| Liu, C | 1 |
| Pusceddu, S | 3 |
| Prinzi, N | 2 |
| Lo Russo, G | 2 |
| Femia, D | 3 |
| Milione, M | 3 |
| Perrone, F | 1 |
| Tamborini, E | 1 |
| Concas, L | 3 |
| Pulice, I | 1 |
| Vernieri, C | 3 |
| Corti, F | 1 |
| Buzzoni, R | 3 |
| de Braud, F | 3 |
| Di Maio, M | 1 |
| Marconcini, R | 1 |
| Spada, F | 1 |
| Massironi, S | 1 |
| Ibrahim, T | 1 |
| Brizzi, MP | 1 |
| Campana, D | 1 |
| Faggiano, A | 1 |
| Giuffrida, D | 1 |
| Rinzivillo, M | 1 |
| Cingarlini, S | 1 |
| Aroldi, F | 1 |
| Antonuzzo, L | 1 |
| Berardi, R | 1 |
| Catena, L | 1 |
| De Divitiis, C | 1 |
| Ermacora, P | 1 |
| Perfetti, V | 1 |
| Fontana, A | 1 |
| Razzore, P | 1 |
| Davì, MV | 1 |
| Cauchi, C | 1 |
| Duro, M | 1 |
| Ricci, S | 1 |
| Fazio, N | 1 |
| Cavalcoli, F | 1 |
| Bongiovanni, A | 1 |
| La Salvia, A | 1 |
| Brighi, N | 1 |
| Colao, A | 1 |
| Puliafito, I | 1 |
| Panzuto, F | 1 |
| Ortolani, S | 1 |
| Zaniboni, A | 1 |
| Di Costanzo, F | 1 |
| Torniai, M | 1 |
| Bajetta, E | 1 |
| Tafuto, S | 1 |
| Garattini, SK | 1 |
| Giacomelli, L | 2 |
| Delle Fave, G | 1 |
| Mazzaferro, V | 2 |
| Burney, S | 1 |
| Khawaja, KI | 1 |
| Saif, MW | 1 |
| Masud, F | 1 |
| Paun, DL | 1 |
| Vija, L | 1 |
| Stan, E | 1 |
| Banica, A | 1 |
| Bobeica, E | 1 |
| Terzea, D | 1 |
| Poiana, C | 1 |
| Badiu, C | 1 |
| Paun, S | 1 |
| Marceglia, S | 1 |
| Leuzzi, L | 1 |
| Formisano, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725] | Phase 2 | 110 participants (Anticipated) | Interventional | 2019-10-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Neuroendocrine Tumors
| Article | Year |
|---|---|
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Topics: Antineoplastic Agents; Comorbidity; Diabetes Mellitus; Everolimus; Humans; Hypoglycemic Agents; Metf | 2016 |
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Topics: Antineoplastic Agents; Comorbidity; Diabetes Mellitus; Everolimus; Humans; Hypoglycemic Agents; Metf | 2016 |
11 other studies available for metformin and Neuroendocrine Tumors
| Article | Year |
|---|---|
EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Therapy, Combination; | 2021 |
EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Therapy, Combination; | 2021 |
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
Topics: Aged; Everolimus; Humans; Metformin; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis | 2023 |
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
Topics: Aged; Everolimus; Humans; Metformin; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis | 2023 |
The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metfor | 2020 |
The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metfor | 2020 |
Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, A | 2020 |
Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, A | 2020 |
Metformin and everolimus in neuroendocrine tumours: A synergic effect?
Topics: Aged; Antineoplastic Agents; Cohort Studies; Diabetes Mellitus; Digestive System Neoplasms; Drug Syn | 2020 |
Metformin and everolimus in neuroendocrine tumours: A synergic effect?
Topics: Aged; Antineoplastic Agents; Cohort Studies; Diabetes Mellitus; Digestive System Neoplasms; Drug Syn | 2020 |
A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tu | 2020 |
A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tu | 2020 |
Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors.
Topics: China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; | 2020 |
Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors.
Topics: China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; | 2020 |
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Gastrointestinal Neoplasms; Huma | 2017 |
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Gastrointestinal Neoplasms; Huma | 2017 |
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Diabetes Mellitus, Type 2; | 2018 |
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Diabetes Mellitus, Type 2; | 2018 |
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Human | 2014 |
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Human | 2014 |
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion from a Meckel diverticulum neuroendocrine tumor: case report.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cushing | 2015 |
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion from a Meckel diverticulum neuroendocrine tumor: case report.
Topics: ACTH Syndrome, Ectopic; Adrenocorticotropic Hormone; Adult; Corticotropin-Releasing Hormone; Cushing | 2015 |